• Home
  • About Journal
    Journal Introduction
    Editorial Board
    Youth Editorial Board
    Cooperating Institutions
    Editorial Department
  • Submission Guidelines
  • Policies & Statements
    Ethical Guidelines for Publication
    Academic Misconduct Statement
    Open Access (OA) Statement
    AIGC Use Statement
  • Journal Subscription
  • Download Center
  • 中文版
Cite this article:
Narh Philip Amor,LIN Ang.Development and evaluation of PreS1-targeted HBV mRNA vaccine[J].Journal Of Pharmaceutical Research,2024,43(11):1041-1044,1108[Click to copy]
【Print this page】      【Download PDF Full Text】   【View/Add Comment】  【Download reader】  【 Close 】
←Previous|Next→ Archive    Advanced Search
This article has been viewed: 2545times   Download 1986次 QR Code for this article
Scan with your phone!
靶向PreS1的HBV mRNA疫苗的开发与免疫原性评价
NarhPhilipAmor(阿莫)1,2,林昂1,2
Font:Larger+|Default|Smaller-
(1.中国药科大学基础医学与临床药学学院,江苏 南京 211198;2.中国药科大学新药安全评价研究中心,江苏 南京 211198)
摘要:
目的 通过靶向HBV PreS1抗原设计并制备具有强免疫原性的治疗性mRNA疫苗。方法 基于中国患者常见的GenotypeC-Adr亚型HBV毒株的PreS1抗原序列,并添加T7 RNA聚合酶启动子、UTR序列和分泌肽,设计并通过不同平台优化了mRNA疫苗序列。将体外转录的mRNA(2 μg/wells)转染到HEK293T细胞中,通过ELISA方法验证PreS1抗原的表达。将mRNA包封在LNP中,通过肌肉注射免疫小鼠。通过ELISA检测血清中的抗体水平,ELISPOT检测脾脏T细胞的抗原特异性应答验证mRNA疫苗的免疫原性。结果 与空白对照组相比,mRNA疫苗组小鼠血清中产生大量PreS1特异性IgG抗体(P<0.05)。ELISPOT结果显示,mRNA疫苗组脾脏T细胞对PreS1肽库刺激特异性产生IFNγ。结论 靶向PreS1的治疗性HBV mRNA疫苗具有良好的免疫原性,在小鼠体内诱导特异性B细胞反应(体液免疫)和T细胞反应(细胞免疫)。
关键词:  乙型肝炎病毒  治疗性mRNA疫苗  脂质纳米颗粒  免疫原性
DOI:10.13506/j.cnki.jpr.2024.11.001
基金项目:国家自然科学基金项目(No.32200764)
Publication Date:November 25, 2024
Development and evaluation of PreS1-targeted HBV mRNA vaccine
Narh Philip Amor1,2,LIN Ang1,2
(1.School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing 211198, China; 2.Center for New Drug Safely Evaluation and Research, China Pharmaceutical University, Nanjing 211198, China)
Abstract:
Objective To design and develop a therapeutic mRNA vaccine encoding HBV PreS1 antigen with strong immunogenicity. Methods Based on the PreS1 antigen sequence of GenotypeC-Adr subtype HBV strains that commonly infect Chinese patients, mRNA vaccine sequences was designed and optimized using different platforms with the addition of T7 RNA polymerase promoter, UTR sequence, and signal peptide. The in-vitro transcribed mRNA (2 μg/well) was transfected into HEK293T cells, and PreS1 antigen expression was verified using ELISA. The mRNA was then efficiently encapsulated with an ionizable lipid-based LNP, and mice were immunized via intramuscular injection. Subsequently, antibody levels in serum were detected using ELISA, and antigen-specific responses of splenic T cells were validated by ELISPOT to assess the immunogenicity of the mRNA vaccine. Results Compared to the control group, mice in the mRNA vaccine groups showed significantly increased levels of PreS1-specific IgG antibodies in serum (P<0.05). The ELISPOT assay demonstrated that splenic T cells from the mRNA vaccine groups produced IFNγ in response to stimulation with PreS1 peptide pools. Conclusion The therapeutic HBV mRNA vaccine encoding PreS1 antigen exhibited robust immunogenicity, inducing specific B cell (humoral immunity) and T cell responses (cellular immunity) in mice.
Key words:  Hepatitis B virus  Therapeutic mRNA vaccine  Lipid nanoparticles  Immunogenicity
Today's Visits:485    Total Visits:2383197
Website copyright:Editorial Board of Journal of Pharmaceutical Research     鲁ICP备17018036号-3     鲁公网安备 37010202001351号
Sponsored by:Shandong Institute for Food and Drug Control Shandong Pharmaceutical Association Address:No.2749 Xinluo Street,High-Tech Zone,Jinan,P.R.China Postcode:250101
Telephone Number:0531-81216586 Email :yaoxueyanjiu@163.com;yaoxueyanjiu@126.com
Technical Support:Beijing Qinyun Technology Co., Ltd.